Home Tags PD-L1

Tag: PD-L1

Updated Results from Trial Shows Enfortumab Vedotin + Pembrolizumab to Shrink...

Updated findings from EV-103, a phase Ib/II clinical trials of enfortumab vedotin* (Padcev™; Astellas Pharma/Seattle Genetics) in combination with pembrolizumab (Keytruda®; Merck Sharp &...

Collaboration to Explore the Safety and Efficacy of Combining Rova-T +...

A new Phase I/II clinical program in which Bristol-Myers Squibb collaborates with AbbVie will evaluate the safety, tolerability and efficacy of the investigational biomarker-specific...

CytomX Therapeutics and Bristol-Myers Squibb Continue Collaboration

CytomX Therapeutics, an oncology-focused biopharmaceutical company based in South San Francisco developing investigational Probody™ therapeutics for the treatment of cancer, earlier today announced that...

California Life Sciences Association Rewards Sutro Biopharma with Outstanding Partner Award

This week, during the California Life Sciences Association (CLSA) annual Pantheon Ceremony (DiNA Awards), Sutro Biopharma received the Outstanding Partner Award. By giving this award to Sutro, the...

Strategic Immuno-Oncology Collaboration Between Celgene and MedImmune Focuses on Non-Hodgkin’s Lymphoma,...

Celgene, headquartered in Summit, New Jersey, and MedImmune (Gaithersburg, Maryland), a wholly owned subsidiary of AstraZeneca, have entered into a strategic collaboration to develop and...

Novel Targeted Lung Cancer Therapies are Expected to Replace Current Conventional...

Lung cancer, which is mostly a disease of the elderly*, is defined as the uncontrolled growth of abnormal cells in one or both lungs.  Approximately 60%...